Clinical trial
An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Pain Due to Osteoarthritis of the Knee Taking WHO Step III Analgesics But Showing a Lack of Tolerability.
NCT00982280 is registered in ClinicalTrials.gov with Grünenthal GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Pain Due to Osteoarthritis of the Knee Taking WHO Step III Analgesics But Showing a Lack of Tolerability.
- Lead sponsor
- Grünenthal GmbH
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- September 30, 2009
- Completion date
- August 31, 2010
- Enrollment
- 82 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.